March 2021

Cordella Pa Sensor

Endotronix Celebrates 100th Implant Of The Cordella™ Pulmonary Artery Pressure Sensor For Proactive, Remote Management Of Heart Failure

Endotronix, Latest News /

Galway, Ireland and Lisle, IL, USA.  March 23, 2021.  Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure, today announced the 100th global implant of the Cordella Pulmonary Artery Pressure Sensor (Cordella Sensor) by Cardiologist and top worldwide implanter Faisal Sharif, MD of Bon Secours Hospital and […]

Endotronix Celebrates 100th Implant Of The Cordella™ Pulmonary Artery Pressure Sensor For Proactive, Remote Management Of Heart Failure Read More »

Fusion Round

Fusion Pharmaceuticals To Expand Pipeline With Acquisition Of IPN-1087, A Small Molecule Targeting NTSR1, From Ipsen.

Fusion, Latest News /

Hamilton, Canada and Boston, USA.  March 2, 2021.  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has entered into an asset purchase agreement (APA) to acquire Ipsen’s (Euronext: IPN; ADR; IPSEY) intellectual property and assets related to IPN-1087. IPN-1087 is a small molecule

Fusion Pharmaceuticals To Expand Pipeline With Acquisition Of IPN-1087, A Small Molecule Targeting NTSR1, From Ipsen. Read More »

Dan Dearen

Endotronix Appoints Industry Veteran Dan Dearen to Board of Directors.

Endotronix, Latest News /

Lisle, IL, USA.  2 March 2021.  Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the appointment of seasoned medical device industry executive Dan Dearen to its Board of Directors.  Mr. Dearen currently serves as the President and Chief Financial Officer of Axonics Modulation

Endotronix Appoints Industry Veteran Dan Dearen to Board of Directors. Read More »

Nick Holsman

Shorla Pharma Announces U.S. Industry Veteran Nicholas Holsman as Chief Commercial Officer.

Latest News, Shorla Pharma /

Clomel, Tipperary, Ireland.  2 March 2021.  Shorla Pharma Limited (‘Shorla’), a specialty pharmaceutical company, announces the appointment of Chief Commercial Officer Nicholas Holsman, a highly experienced U.S. industry executive with in-depth experience in scaling oncology & specialty pharma enterprises. Shorla specializes in developing innovative oncology drugs, with a focus on orphan and pediatric cancers. With

Shorla Pharma Announces U.S. Industry Veteran Nicholas Holsman as Chief Commercial Officer. Read More »

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top